达拉非尼联合曲美替尼治疗复发/难治性BRAF V600E突变阳性毛细胞白血病患者
这项开放标签2期研究纳入55例复发/难治性BRAF V600E突变阳性毛细胞白血病患者,接受达拉非尼150 mg每日两次联合曲美替尼2 mg每日一次治疗。研究者评估的客观缓解率为89.0%(95%CI 77.8%-95.9%),24个月缓解持续时间97.7%,24个月无进展生存率和总生存率分别为94.4%和94.5%。常见治疗相关不良事件为发热(58.2%)、寒战(47.3%)和高血糖(40.0%)。
要点
- 达拉非尼联合曲美替尼在复发/难治性BRAF V600E突变阳性毛细胞白血病中客观缓解率达89.0%。
- 65.5%患者达完全缓解,其中49.1%伴微小残留病阳性,9.1%经骨髓活检免疫组化确认微小残留病阴性。
- 24个月缓解持续时间97.7%,24个月无进展生存率94.4%,总生存率94.5%。
核心结论
- 达拉非尼联合曲美替尼在复发/难治性BRAF V600E突变阳性毛细胞白血病中显示出持久缓解,安全性可控,与此前其他适应症中的观察一致。
- 作者认为该方案应被视为复发/难治性BRAF V600E突变阳性毛细胞白血病的一种不含利妥昔单抗的治疗选择。
研究设计与样本
- 开放标签2期研究,纳入对一线嘌呤类似物治疗难治或既往≥2线治疗后复发的BRAF V600E突变阳性毛细胞白血病患者。
- 患者接受达拉非尼150 mg每日两次联合曲美替尼2 mg每日一次,直至疾病进展、不可接受毒性或死亡。
- 主要终点为研究者根据改编自美国国家综合癌症网络共识决议指南的标准评估的客观缓解率;次要终点包括缓解持续时间、无进展生存、总生存和安全性。
- 共纳入55例BRAF V600E突变阳性毛细胞白血病患者。
- 试验注册于www.clinicaltrials.gov,编号NCT02034110。
主要发现
- 研究者评估的客观缓解率为89.0%(95%CI 77.8%-95.9%)。
- 65.5%患者达完全缓解:无微小残留病者9.1%(骨髓活检免疫组化阴性)、12.7%(骨髓穿刺流式细胞术阴性)、16.4%(免疫组化和/或流式细胞术结果阴性);伴微小残留病者49.1%。
- 23.6%患者达部分缓解。
- 24个月缓解持续时间为97.7%,24个月无进展生存率为94.4%,24个月总生存率为94.5%。
- 最常见治疗相关不良事件为发热(58.2%)、寒战(47.3%)和高血糖(40.0%)。
关键数值与推荐
- 客观缓解率89.0%(95%CI 77.8%-95.9%),完全缓解率65.5%,部分缓解率23.6%。
- 24个月缓解持续时间97.7%,24个月无进展生存率94.4%,24个月总生存率94.5%。
- 常见治疗相关不良事件:发热58.2%、寒战47.3%、高血糖40.0%。
临床怎么用
- 作者认为达拉非尼联合曲美替尼应被视为复发/难治性BRAF V600E突变阳性毛细胞白血病的一种不含利妥昔单抗的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BRAF V600E is the key oncogenic driver mutation in hairy cell leukemia (HCL). We report the efficacy and safety of dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive HCL. This open-label, phase 2 study enrolled patients with BRAF V600E mutation-positive HCL refractory to first-line treatment with a purine analog or relapsed after ≥2 prior lines of treatment. Patients received dabrafenib 150 mg twice daily plus trametinib 2 mg once daily until disease progression, unacceptable toxicity, or death. The primary endpoint was investigator-assessed objective response rate (ORR) per criteria adapted from National Comprehensive Cancer Network-Consensus Resolution guidelines. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Fifty-five patients with BRAF V600E mutation-positive HCL were enrolled. The investigator-assessed ORR was 89.0% (95% confidence interval, 77.8%-95.9%); 65.5% of patients had a complete response (without minimal residual disease [MRD]: 9.1% [negative immunohistochemistry of bone marrow {BM} biopsy], 12.7% [negative BM aspirate flow cytometry {FC}], 16.4% [negative immunohistochemistry and/or FC results]; with MRD, 49.1%), and 23.6% had a partial response. The 24-month DOR was 97.7% with 24-month PFS and OS rates of 94.4% and 94.5%, respectively. The most common treatment-related adverse events were pyrexia (58.2%), chills (47.3%), and hyperglycemia (40.0%). Dabrafenib plus trametinib demonstrated durable responses with a manageable safety profile consistent with previous observations in other indications and should be considered as a rituximab-free therapeutic option for patients with relapsed/refractory BRAF V600E mutation-positive HCL. This trial is registered at www.clinicaltrials.gov as #NCT02034110.
引用
- Kreitman RJ, Moreau P, Ravandi F, et al. Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia. Blood. 2023. PMID: 36108341. doi:10.1182/blood.2021013658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。